Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.33 |
| ▸ | BRD2 | P25440 | 6/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22900461 | 0.93 | BRD4 (0.34) | BRD4BRD3CREBBPBRD2MDM2 | |
| SCHEMBL22900431 | 0.88 | CREBBP (0.33) | BRD4BRD3CREBBPBRD2MDM2 | |
| SCHEMBL22900398 | 0.85 | BRD4 (0.36) | BRD4BRD3CREBBPBRD2MDM2 | |
| SCHEMBL22900453 | 0.84 | BRD4 (0.36) | BRD4BRD3CREBBPBRD2MDM2 | |
| SCHEMBL22900324 | 0.82 | CREBBP (0.35) | BRD4BRD3CREBBPBRD2MDM2 | |
| SCHEMBL22900327 | 0.80 | BRD4 (0.34) | BRD4BRD3CREBBPBRD2MDM2 | |
| SCHEMBL22900326 | 0.79 | BRD2 (0.40) | BRD4BRD3CREBBPBRD2MDM2 | |
| SCHEMBL22900416 | 0.78 | CREBBP (0.34) | BRD4BRD3CREBBPBRD2MDM2 | |
| SCHEMBL22900458 | 0.77 | BRD2 (0.38) | BRD4BRD3CREBBPBRD2QPCT | |
| SCHEMBL22900485 | 0.76 | ALDH1A1 (0.43) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021009068-A1 | N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME | SCENIC IMMUNOLOGY B.V. (NL) | 2021-01-21 | — | — | WO | disclosed |